Pfizer Inc. (NYSE:PFE) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET
Company Participants
Francesca DeMartino – Chief IRO and SVP
Albert Bourla – Chairman and CEO
David Denton – CFO
Conference Call Participants
Chris Schott – JPMorgan
Geoff Meacham – Citibank
Steve Scala – TD Securities
Tim Anderson – Bank of America
Chris Shibutani – Goldman Sachs
Trung Huynh – UBS
Vamil Divan – Guggenheim
Evan Seigerman – BMO Capital Markets
Operator
Good day, everyone, and welcome to Pfizer’s Analyst and Investor Call to Review Full Year 2025 Financial Guidance. Today’s call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma’am.
Francesca DeMartino
Good morning, and welcome to Pfizer’s 2025 financial guidance call. I’m Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our 2025 financial guidance via a press release that is available on our website at pfizer.com. I’m joined today by Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO. Albert and Dave have some prepared remarks, and we will then open the call for questions.
Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures. I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning, and the disclosures in our SEC filings which are all available on the IR website on pfizer.com. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call’s original date and we undertake no obligation to update or revise any
#Pfizer #PFE #FullYear #Financial #Guidance #Conference #Call #Transcript